French ophthalmology company Nicox SA entered into an exclusive research and license option agreement with Glaukos Corp. to develop NCX 1728, a novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor, the company announced in a press release.

Under this agreement, Glaukos will fund a preclinical research program to evaluate the use of NCX 1728 for neuroprotection and the reduction of IOP in glaucoma, as well as treatment for other retinal diseases. The program will be overseen by a joint steering committee, with Glaukos holding an option to license NCX 1728 for global development within a specified timeline.